Blood Glucose Monitoring Systems Market - Size, Share, Trends, Competitive Landscape, and Forecast - 2034 | Wearable CGM and AI Drive 7.72% CAGR to $25.50 Billion

Recurring sensor revenue, OTC expansion, longer-wear devices and digital health integration strengthen ROI as continuous, wearable and home-care monitoring lead adoption.

Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -- "Blood Glucose Monitoring Systems - Market Insights, Competitive Landscape, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.

The global blood glucose monitoring systems market was valued at USD 13.06 billion in 2025 and is projected to reach USD 25.50 billion by 2034, expanding at a compound annual growth rate of 7.72% from 2026-2034. Market growth is supported by the increasing prevalence of diabetes and impaired glucose tolerance, wider adoption of continuous glucose monitoring systems, favorable reimbursement policies, technological innovation, and growing demand for minimally invasive monitoring.

Continuous glucose monitoring systems represented 62% of the market in 2025, making them the leading product category. Wearable devices accounted for 58% of market revenue, while home care settings held a 60% share of end-user demand. North America led the global market with a 38% share in 2025, while Asia-Pacific is projected to record the fastest growth through 2034.

Blood Glucose Monitoring Systems Market Growth Drivers

The expanding global diabetes population remains the principal driver of demand. The International Diabetes Federation reported that 537 million adults aged 20 to 79 were living with diabetes in 2021. This figure is projected to increase to 643 million by 2030 and 783 million by 2045. More than 75% of adults with diabetes reside in low- and middle-income countries, creating substantial opportunities for cost-effective monitoring technologies. An additional 541 million adults have impaired glucose tolerance, further expanding the population that may Benefit from regular glucose monitoring.

The transition from intermittent testing to continuous glucose monitoring is also reshaping the market. Real-time and intermittently scanned systems offer improved convenience, treatment optimization, and patient adherence, particularly for insulin-dependent populations. Integration with smartphones, cloud platforms, insulin pumps, and automated insulin delivery systems is increasing the clinical and commercial value of these products.

• Improved sensor accuracy and longer wear durations
• Calibration-free and minimally invasive monitoring technologies
• Artificial-intelligence-driven glucose prediction and personalized insights
• Cloud-based data sharing and remote patient monitoring
• Growing use of telehealth and physician dashboards
• Favorable reimbursement for meters, test strips, and continuous glucose monitoring systems
• Increasing demand from aging populations with higher diabetes prevalence

Market Restraints

Accuracy, affordability, and reimbursement variability continue to affect market adoption. False readings or technical errors can contribute to inappropriate insulin dosing and increase the risk of hypoglycemia or hyperglycemia. Sensor calibration, interference, and differences between interstitial and blood glucose measurements remain important considerations, particularly when continuous glucose monitoring data are used by automated insulin delivery systems.

The higher cost of continuous glucose monitoring systems compared with finger-stick testing may limit access in markets without adequate insurance coverage. Recurring sensor and consumable expenses, skin reactions, device discomfort, and competition from low-cost meters and strips also present challenges. Manufacturers must balance product innovation with affordability, clinical reliability, and accessibility across different healthcare systems.

Blood Glucose Monitoring Systems Market Segment Analysis

By Product Type: Continuous glucose monitoring systems held a 62% market share in 2025. Growth is being driven by connected sensors, longer wear periods, automated alerts, digital health integration, and expanding availability for non-insulin and over-the-counter users. Self-monitoring blood glucose systems remain important in cost-sensitive markets and lower-intensity care settings due to their established availability and lower upfront expense.

By Modality: Wearable products accounted for 58% of the market in 2025. Their leadership reflects strong adoption of body-worn continuous monitoring sensors and increased demand for connected, long-wear technologies. Non-wearable meters and test strips continue to serve patients seeking intermittent testing and cost-effective glucose management.

By End-User: Home care settings led the market with a 60% share in 2025. This position is supported by greater emphasis on self-management, remote care, connected health platforms, and reduced dependence on facility-based testing. Hospitals and other clinical settings remain significant users for diagnosis, treatment management, and inpatient monitoring.

Regional Market Outlook

North America: North America accounted for 38% of global market revenue in 2025. The region benefits from strong reimbursement, advanced healthcare infrastructure, high adoption of connected monitoring, and the presence of leading medical technology companies. According to the Centers for Disease Control and Prevention, 38.4 million people in the United States, representing 11.6% of the population, had diabetes in 2021. Product clearances, automated insulin delivery adoption, and expansion into over-the-counter metabolic health applications are expected to support continued regional leadership.

Europe: Europe represents a large and technologically advanced market supported by established public healthcare systems and clinical adoption of continuous glucose monitoring. Germany, France, and the United Kingdom are key national markets. Growth prospects remain influenced by country-specific reimbursement policies, public healthcare budgets, and access to connected monitoring technologies.

Asia-Pacific: Asia-Pacific is forecast to achieve the fastest growth through 2034. Rising diabetes prevalence, urbanization, expanding healthcare access, higher disposable incomes, and greater awareness of glucose management are increasing demand. China has a large diabetic population and a rapidly developing domestic medical device industry. India offers substantial growth potential as access improves, while Japan combines an aging population with advanced adoption of monitoring technologies.

Rest of the World: The Middle East, Africa, and South America offer developing opportunities. Gulf countries have high diabetes prevalence and relatively advanced healthcare systems, while Brazil and Mexico support expanding diabetes-care markets. Affordability and healthcare access remain constraints in parts of Africa, increasing the importance of cost-appropriate monitoring products.

Competitive Landscape

The blood glucose monitoring systems market is moderately consolidated. Competition centers on sensor accuracy, wear duration, connectivity, clinical evidence, regulatory clearance, reimbursement status, portfolio breadth, and integration with automated insulin delivery and digital health platforms. Development pipelines increasingly focus on needle-free and non-invasive monitoring, implantable sensors, over-the-counter products, predictive analytics, and closed-loop insulin delivery.

Leading companies operating in the market include:

• Medtronic plc
• Abbott
• F. Hoffmann-La Roche Ltd.
• LifeScan, Inc.
• Dexcom, Inc.
• ARKRAY, Inc.
• Senseonics Holdings, Inc.
• WaveForm Technologies, Inc.
• B. Braun Melsungen AG
• Ascensia Diabetes Care Holdings AG

Abbott and Dexcom maintain prominent positions in continuous glucose monitoring, while Medtronic has a strong presence in systems integrated with insulin pumps and automated insulin delivery. Roche , LifeScan, Ascensia, ARKRAY, and i-SENS are established participants in meters and test strips. Senseonics competes in the long-wear implantable monitoring segment.

Recent Market Development

In August 2025, Signos launched the Signos Glucose Monitoring System for over-the-counter weight management. The system combines the Stelo by Dexcom glucose biosensor with an artificial-intelligence-powered platform that delivers personalized insights related to food, activity, stress, sleep, and metabolic health. The launch reflects the expansion of continuous glucose monitoring beyond diabetes management into weight management, wellness, and broader metabolic health applications.

Market Segmentation

• Product Type: Self-Monitoring Blood Glucose Systems and Continuous Glucose Monitoring Systems
• Modality: Wearable and Non-Wearable
• End-User: Hospitals, Home Care Settings, and Others
• Geography: North America, Europe, Asia-Pacific, and Rest of the World

Continued innovation, broader reimbursement, rising diabetes prevalence, and the integration of glucose data with digital health ecosystems are expected to sustain long-term blood glucose monitoring systems market growth. Continuous glucose monitoring and wearable technologies are positioned to capture an increasing share of revenue as manufacturers extend their products to larger patient, consumer, and wellness populations.

Key Topics Covered:

1. Blood Glucose Monitoring Systems Market Introduction
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Market Overview at a Glance

2. Blood Glucose Monitoring Systems Market Executive Summary
2.1. Key Highlights and Market Snapshot

3. Blood Glucose Monitoring Systems Market Key Factors Analysis
3.1. Market Drivers
3.1.1. Rising Global Prevalence of Diabetes
3.1.2. Shift Toward Continuous Glucose Monitoring
3.1.3. Technological Advancement in Sensors and Connectivity
3.1.4. Favorable Reimbursement Policies in Major Markets
3.2. Market Restraints
3.2.1. False Readings and Incorrect Insulin Dosing
3.2.2. Availability of Alternative Options
3.2.3. Cost and Reimbursement Constraints
3.3. Market Opportunities
3.3.1. Adoption of Digital Health Solutions
3.3.2. Integration with Smartphones, Wearables, and IoT Devices

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis
5.1. The United States
5.2. Europe
5.3. Japan
5.4. China

6. Blood Glucose Monitoring Systems Market Porter's Five Forces Analysis
6.1. Bargaining Power of Suppliers
6.2. Bargaining Power of Consumers
6.3. Threat of New Entrants
6.4. Threat of Substitutes
6.5. Competitive Rivalry

7. Blood Glucose Monitoring Systems Market Assessment
7.1. By Product Type
7.1.1. Self-Monitoring Blood Glucose Systems
7.1.2. Continuous Glucose Monitoring Systems
7.2. By Modality
7.2.1. Wearable
7.2.2. Non-Wearable
7.3. By End-User
7.3.1. Hospitals
7.3.2. Home Care Settings
7.3.3. Others
7.4. By Geography
7.4.1. North America
7.4.1.1. United States Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.1.2. Canada Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.1.3. Mexico Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.2. Europe
7.4.2.1. France Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.2.2. Germany Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.2.3. United Kingdom Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.2.4. Italy Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.2.5. Spain Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.2.6. Rest of Europe Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.3. Asia-Pacific
7.4.3.1. China Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.3.2. Japan Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.3.3. India Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.3.4. Australia Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.3.5. South Korea Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.3.6. Rest of Asia-Pacific Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.4. Rest of the World
7.4.4.1. Middle East Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.4.2. Africa Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)
7.4.4.3. South America Blood Glucose Monitoring Systems Market Size in USD million (2023-2034)

8. Blood Glucose Monitoring Systems Market Competitive Landscape
8.1. Competitive Analysis
8.2. Company Share Analysis ( PREMIUM Offering)

9. Blood Glucose Monitoring Systems Market Startup Funding and Investment Trends

10. Blood Glucose Monitoring Systems Market Company and Product Profiles
10.1. Profile Coverage
10.1.1. Company Overview
10.1.2. Company Snapshot
10.1.3. Financial Overview
10.1.4. Product Listing
10.1.5. Strategic Initiatives / Entropy
10.2. Companies Profiled
10.2.1. Medtronic plc
10.2.2. Abbott
10.2.3. F. Hoffmann-La Roche Ltd.
10.2.4. LifeScan, Inc.
10.2.5. Dexcom, Inc.
10.2.6. ARKRAY, Inc.
10.2.7. Senseonics Holdings, Inc.
10.2.8. WaveForm Technologies, Inc.
10.2.9. B. Braun Melsungen AG
10.2.10. Ascensia Diabetes Care Holdings AG

11. KOL Views

12. Project Approach

13. About the Publisher

14. Disclaimer and Contact Us

List of Tables [28]

List of Figures [38]

A selection of companies mentioned in this report includes, but is not limited to:

• Medtronic plc
• Abbott
• F. Hoffmann-La Roche Ltd.
• LifeScan, Inc.
• Dexcom, Inc.
• ARKRAY, Inc.
• Senseonics Holdings, Inc.
• WaveForm Technologies, Inc.
• B. Braun Melsungen AG
• Ascensia Diabetes Care Holdings AG

For more information about this report visit https://www.researchandmarkets.com/r/hw3qxr

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900